ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses12.28 M10.78 M15.02 M20.67 M21.01 M67.48 MResearch & development24.75 M20.81 M29.15 M24.79 M28.99 M103.74 MOperating income37.03 M31.59 M44.17 M43.76 M40.72 M160.24 MNon-Operating Income, Total908 K960 K1 M932 K1.22 M4.11 MInterest expense, net of interest capitalized1.15 M1.15 M192 K212 K319 K1.87 MNon-Operating Income, excl. Interest Expenses-317 K-178 K768 K610 K863 K2.06 MUnusual income/expense77 K-8 00040 K110 K37 K179 KPretax income37.87 M32.48 M46.99 M-18.66 M-10.18 M50.62 MEquity in earnings——————Taxes0185 K000185 KNon-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations23.97 M64.55 M52.1 M25.93 M98.52 M241.11 MDiscontinued operations——————Net income23.97 M64.55 M52.1 M25.93 M98.52 M241.11 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders23.97 M64.55 M52.1 M46.25 M98.52 M261.43 MBasic earnings per share (Basic EPS)-0.6-1.49-0.96-0.39-1.35-4.19Diluted earnings per share (Diluted EPS)-0.6-1.49-0.96-0.62-1.35-4.42Average basic shares outstanding40.26 M35.71 M54.17 M66.14 M73.16 M229.19 MDiluted shares outstanding40.26 M35.71 M54.17 M74.04 M73.16 M237.08 MEBITDA———-43.32 M-38.75 M—EBIT———-43.57 M-39.47 M—Cost of revenue———128 K300 K—Other cost of goods sold——————Depreciation & amortization (cash flow)-194 K-200 K40 K255 K720 K815 K
Verastem Inc
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.